Roth MKM lowered the firm’s price target on CervoMed (CRVO) to $4 from $45 and keeps a Buy rating on the shares. The company ...

BOSTON, Dec. 12, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO) (the “Company”), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced ...

The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant designed to inhibit p38 mitogen-activated protein kinase alpha. Neflamapimod ...

The latest in health news includes Zealand Pharma's obesity drug trial, a record dengue outbreak in the Americas, CervoMed's ...

CervoMed Inc. (NASDAQ:CRVO) stock is trading lower after the company revealed topline data from the RewinD-LB Phase 2b ...

Ollie's Bargain Outlet Holdings, Inc. OLLI shares jumped over 14% on Tuesday after the company released third-quarter results ...

CervoMed shares collapsed Tuesday after the clinical-stage company reported a mid-stage study failure of its lead program. Shares of the Boston company were recently changing hands at $2.26, down 78%, ...

Boston-based CervoMed (CRVO) said the Phase 2b trial of its neflamapimod did not meet significant statistical thresholds for its primary endpoint of a change in the Clinical Dementia Rating Sum of ...

CervoMed’s dementia drug disappoints in Phase 2: The drugmaker’s neflamapimod missed both the primary and key secondary endpoints in a mid-stage trial of 159 patients with dementia with Lewy bodies.

CervoMed said on Tuesday its experimental drug for a common degenerative brain disease did not meet the main or secondary ...

CervoMed Inc. (CRVO) announced Tuesday that its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia ...

U.S. stocks traded mixed this morning, with the Dow Jones index falling around 150 points on Tuesday. Following the market ...